Novartis Correlations
| NOVN Stock | CHF 91.56 0.57 0.63% |
The current 90-days correlation between Novartis AG and Roche Holding AG is 0.28 (i.e., Modest diversification). The correlation of Novartis is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
Novartis Correlation With Market
Modest diversification
The correlation between Novartis AG and DJI is 0.29 (i.e., Modest diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Novartis AG and DJI in the same portfolio, assuming nothing else is changed.
Novartis |
The ability to find closely correlated positions to Novartis could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Novartis when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Novartis - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Novartis AG to buy it.
Moving together with Novartis Stock
| 0.74 | ROG | Roche Holding AG | PairCorr |
| 0.71 | RO | Roche Holding AG | PairCorr |
| 0.68 | SNBN | Schweizerische Nationalbank | PairCorr |
| 0.89 | NESN | Nestl SA | PairCorr |
Moving against Novartis Stock
| 0.58 | SLHN | Swiss Life Holding | PairCorr |
| 0.56 | ZURN | Zurich Insurance | PairCorr |
| 0.46 | UBSG | UBS Group AG | PairCorr |
| 0.4 | SREN | Swiss Re AG | PairCorr |
Related Correlations Analysis
| 0.76 | -0.6 | -0.42 | -0.23 | ROG | ||
| 0.76 | -0.78 | -0.38 | -0.65 | NESN | ||
| -0.6 | -0.78 | 0.33 | 0.73 | ZURN | ||
| -0.42 | -0.38 | 0.33 | 0.22 | SREN | ||
| -0.23 | -0.65 | 0.73 | 0.22 | UBSG | ||
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Novartis Stock performing well and Novartis Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Novartis' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| ROG | 0.85 | (0.20) | 0.00 | 66.12 | 0.00 | 1.13 | 4.16 | |||
| NESN | 0.70 | (0.24) | 0.00 | (6.52) | 0.00 | 1.31 | 4.86 | |||
| ZURN | 0.58 | 0.10 | 0.07 | 0.31 | 0.48 | 1.19 | 3.80 | |||
| SREN | 1.06 | 0.16 | 0.09 | 0.46 | 1.01 | 2.75 | 8.96 | |||
| UBSG | 1.07 | 0.02 | 0.02 | 0.10 | 1.23 | 2.05 | 7.34 |
Be your own money manager
Our tools can tell you how much better you can do entering a position in Novartis without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Analyst Advice Now
Analyst AdviceAnalyst recommendations and target price estimates broken down by several categories |
| All Next | Launch Module |
Novartis Corporate Management
Elected by the shareholders, the Novartis' board of directors comprises two types of representatives: Novartis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Novartis. The board's role is to monitor Novartis' management team and ensure that shareholders' interests are well served. Novartis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Novartis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Richard Saynor | Chief Sandoz | Profile | |
| Steffen Lang | Pres Operations | Profile | |
| MarieFrance Tschudin | Pres Officer | Profile | |
| Paul Penepent | Head Accounting | Profile | |
| Samir MD | Global Relations | Profile | |
| Robert PharmD | Chief Officer | Profile | |
| Klaus Moosmayer | Risk Ethics | Profile |